Logo image of LEGN

LEGEND BIOTECH CORP-ADR (LEGN) Stock Fundamental Analysis

NASDAQ:LEGN - US52490G1022 - ADR

34.73 USD
+0.36 (+1.05%)
Last: 8/29/2025, 8:00:02 PM
34.85 USD
+0.12 (+0.35%)
After Hours: 8/29/2025, 8:00:02 PM
Fundamental Rating

4

Taking everything into account, LEGN scores 4 out of 10 in our fundamental rating. LEGN was compared to 542 industry peers in the Biotechnology industry. While LEGN seems to be doing ok healthwise, there are quite some concerns on its profitability. LEGN is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year LEGN has reported negative net income.
LEGN had a negative operating cash flow in the past year.
In the past 5 years LEGN always reported negative net income.
In the past 5 years LEGN always reported negative operating cash flow.
LEGN Yearly Net Income VS EBIT VS OCF VS FCFLEGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

Looking at the Return On Assets, with a value of -19.25%, LEGN is in the better half of the industry, outperforming 77.49% of the companies in the same industry.
LEGN has a Return On Equity of -31.42%. This is in the better half of the industry: LEGN outperforms 76.38% of its industry peers.
Industry RankSector Rank
ROA -19.25%
ROE -31.42%
ROIC N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
LEGN Yearly ROA, ROE, ROICLEGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

LEGN has a Gross Margin of 62.51%. This is in the better half of the industry: LEGN outperforms 78.97% of its industry peers.
LEGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LEGN Yearly Profit, Operating, Gross MarginsLEGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

4

2. Health

2.1 Basic Checks

LEGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
LEGN has more shares outstanding than it did 1 year ago.
LEGN has more shares outstanding than it did 5 years ago.
LEGN has a worse debt/assets ratio than last year.
LEGN Yearly Shares OutstandingLEGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
LEGN Yearly Total Debt VS Total AssetsLEGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

LEGN has an Altman-Z score of 7.44. This indicates that LEGN is financially healthy and has little risk of bankruptcy at the moment.
LEGN has a Altman-Z score of 7.44. This is amongst the best in the industry. LEGN outperforms 81.55% of its industry peers.
LEGN has a Debt/Equity ratio of 0.37. This is a healthy value indicating a solid balance between debt and equity.
LEGN has a Debt to Equity ratio of 0.37. This is in the lower half of the industry: LEGN underperforms 71.22% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Altman-Z 7.44
ROIC/WACCN/A
WACC9.61%
LEGN Yearly LT Debt VS Equity VS FCFLEGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

LEGN has a Current Ratio of 4.71. This indicates that LEGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.71, LEGN is in line with its industry, outperforming 51.48% of the companies in the same industry.
LEGN has a Quick Ratio of 4.57. This indicates that LEGN is financially healthy and has no problem in meeting its short term obligations.
LEGN has a Quick ratio (4.57) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.71
Quick Ratio 4.57
LEGN Yearly Current Assets VS Current LiabilitesLEGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

7

3. Growth

3.1 Past

LEGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.18%.
LEGN shows a strong growth in Revenue. In the last year, the Revenue has grown by 74.75%.
LEGN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 59.90% yearly.
EPS 1Y (TTM)-12.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-580%
Revenue 1Y (TTM)74.75%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%36.74%

3.2 Future

The Earnings Per Share is expected to grow by 37.49% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 37.00% on average over the next years. This is a very strong growth
EPS Next Y7.73%
EPS Next 2Y62.64%
EPS Next 3Y44.97%
EPS Next 5Y37.49%
Revenue Next Year69.61%
Revenue Next 2Y60.81%
Revenue Next 3Y52.01%
Revenue Next 5Y37%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
LEGN Yearly Revenue VS EstimatesLEGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
LEGN Yearly EPS VS EstimatesLEGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

LEGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 56.67, which means the current valuation is very expensive for LEGN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of LEGN indicates a rather cheap valuation: LEGN is cheaper than 89.30% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.76. LEGN is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 56.67
LEGN Price Earnings VS Forward Price EarningsLEGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LEGN Per share dataLEGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates LEGN does not grow enough to justify the current Price/Earnings ratio.
LEGN's earnings are expected to grow with 44.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y62.64%
EPS Next 3Y44.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LEGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEGEND BIOTECH CORP-ADR

NASDAQ:LEGN (8/29/2025, 8:00:02 PM)

After market: 34.85 +0.12 (+0.35%)

34.73

+0.36 (+1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners47.87%
Inst Owner Change-3.54%
Ins Owners0.08%
Ins Owner ChangeN/A
Market Cap6.37B
Analysts83.57
Price Target76.34 (119.81%)
Short Float %8.64%
Short Ratio5.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-239.55%
Min EPS beat(2)-351.12%
Max EPS beat(2)-127.98%
EPS beat(4)1
Avg EPS beat(4)-96.8%
Min EPS beat(4)-351.12%
Max EPS beat(4)143.99%
EPS beat(8)5
Avg EPS beat(8)-30.97%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.98%
Min Revenue beat(2)-1.23%
Max Revenue beat(2)9.2%
Revenue beat(4)3
Avg Revenue beat(4)4.83%
Min Revenue beat(4)-1.23%
Max Revenue beat(4)9.2%
Revenue beat(8)4
Avg Revenue beat(8)1.39%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.82%
PT rev (3m)-2.67%
EPS NQ rev (1m)-79.56%
EPS NQ rev (3m)58.68%
EPS NY rev (1m)-53.09%
EPS NY rev (3m)-36.95%
Revenue NQ rev (1m)-0.7%
Revenue NQ rev (3m)3.11%
Revenue NY rev (1m)2.39%
Revenue NY rev (3m)3.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 56.67
P/S 8
P/FCF N/A
P/OCF N/A
P/B 6.15
P/tB 6.17
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)0.61
Fwd EY1.76%
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.5
OCFYN/A
SpS4.34
BVpS5.64
TBVpS5.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.25%
ROE -31.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.51%
FCFM N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 67.19%
Cap/Sales 1.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.71
Quick Ratio 4.57
Altman-Z 7.44
F-Score3
WACC9.61%
ROIC/WACCN/A
Cap/Depr(3y)97.56%
Cap/Depr(5y)226.91%
Cap/Sales(3y)9.76%
Cap/Sales(5y)32.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-580%
EPS Next Y7.73%
EPS Next 2Y62.64%
EPS Next 3Y44.97%
EPS Next 5Y37.49%
Revenue 1Y (TTM)74.75%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%36.74%
Revenue Next Year69.61%
Revenue Next 2Y60.81%
Revenue Next 3Y52.01%
Revenue Next 5Y37%
EBIT growth 1Y41.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.34%
EBIT Next 3Y60.83%
EBIT Next 5Y36.12%
FCF growth 1Y61.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.38%
OCF growth 3YN/A
OCF growth 5YN/A